Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 8, 2014

View Archived Issues

Redx Pharma and AstraZeneca to target genetic drivers of tumor growth and survival

Ludwig Cancer Research and Cancer Research Institute collaborate with VentiRx on motolimod trial

Sirona Biochem reports preclinical data for SBM-TFC-039

Herbosomes of P. granatum extracts to enhance bioavailability

RedHill Biopharma begins phase III study of RHB-102 for gastroenteritis

Novira advances NVR-1221 for HBV infection into phase Ib studies

Lilly's insulin peglispro shows HbA1c superiority over insulin glargine in type 1 diabetes

Conatus Pharmaceuticals begins two phase II trials of emricasan

MITOCARE trial does not demonstrate a protective effect for TRO-40303

Japanese researchers divulge new anti-semaphorin 3A MAbs

AstraZeneca presents promising clinical and non-clinical results for AZD-0914

Tricida confirms new clinical candidate for cardiorenal disease

Aesculap Biologics confirms first human implantation of Novocart 3D

Recro Pharma to close phase II pain trial of intranasal dexmedetomidine following interim analysis

Kamada's inhaled API misses endpoints in phase II/III trial

Chugai Pharmaceutical launches ALK inhibitor Alecensa

Tracon Pharmaceuticals begins phase II trial of TRC-105 in soft tissue sarcoma

FDA approves Keryx Biopharmaceuticals' ferric citrate

Soligenix acquires hypericin photodynamic therapy

FDA accepts filing of Actavis' NDA for ceftazidime/avibactam

Researchers sequence Ebola virus genomes from current outbreak

FDA removes partial clinical hold on ipafricept

Allergan discloses new S1P1 receptor modulators

NIAID's Ebola vaccine is first to provide durable protection in macaques

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 7, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...